Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Antibody responses to a synthetic peptide‐based malaria vaccine candidate: influence of sequence variants of the peptide

Antibody responses to a synthetic peptide‐based malaria vaccine candidate: influence of sequence... A synthetic peptide (Asn‐Ala‐Asn‐Pro)3, representing a protective sequence from the sporozoite stage of Plasmodium falciparum, conjugated to tetanus toxoid has undergone clinical testing. Although some protection was obtained, anti‐parasite responses were generally low. In attempting to improve the anti‐parasite protein antibody response, we evaluated the efficacy of tetanus toxoid conjugates containing seven sequence variants of the peptide. Most of the conjugates tested in both mice and monkeys elicited anti‐peptide antibodies with fine specificity differences, although there was a broad degree of cross‐reactivity. In general, each conjugate tested evoked similarly high anti‐sporozoite antibody responses in both species and, thus, based on antibody titer no evidence for a superior vaccine candidate was obtained. The biological activity of one antiserum actually increased the penetration of sporozoites into human liver cells. In contrast, antisera against the other conjugates inhibited sporozoite penetration, but to a similar degree. Based on these two criteria, none of the other conjugates would appear to be better vaccine candidates than the original conjugate. The lack of concordance between anti‐peptide or anti‐sporozoite titers and inhibitory activity in the case of one antiserum indicates that these two measures of antibody cannot always be used for predicting anti‐sporozoite activity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Immunology Wiley

Antibody responses to a synthetic peptide‐based malaria vaccine candidate: influence of sequence variants of the peptide

Download PDF
7 pages

Loading next page...
 
/lp/wiley/antibody-responses-to-a-synthetic-peptide-based-malaria-vaccine-mTOG0B0Ihp

References (32)

Publisher
Wiley
Copyright
Copyright © 1991 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
ISSN
0014-2980
eISSN
1521-4141
DOI
10.1002/eji.1830210626
pmid
2044658
Publisher site
See Article on Publisher Site

Abstract

A synthetic peptide (Asn‐Ala‐Asn‐Pro)3, representing a protective sequence from the sporozoite stage of Plasmodium falciparum, conjugated to tetanus toxoid has undergone clinical testing. Although some protection was obtained, anti‐parasite responses were generally low. In attempting to improve the anti‐parasite protein antibody response, we evaluated the efficacy of tetanus toxoid conjugates containing seven sequence variants of the peptide. Most of the conjugates tested in both mice and monkeys elicited anti‐peptide antibodies with fine specificity differences, although there was a broad degree of cross‐reactivity. In general, each conjugate tested evoked similarly high anti‐sporozoite antibody responses in both species and, thus, based on antibody titer no evidence for a superior vaccine candidate was obtained. The biological activity of one antiserum actually increased the penetration of sporozoites into human liver cells. In contrast, antisera against the other conjugates inhibited sporozoite penetration, but to a similar degree. Based on these two criteria, none of the other conjugates would appear to be better vaccine candidates than the original conjugate. The lack of concordance between anti‐peptide or anti‐sporozoite titers and inhibitory activity in the case of one antiserum indicates that these two measures of antibody cannot always be used for predicting anti‐sporozoite activity.

Journal

European Journal of Immunology – Wiley

Published: Jun 1, 1991

There are no references for this article.